FOLD - Amicus Therapeutics, Inc.
NEXT EARNINGS:
Feb 25, 2026
(today)
EPS Est: $0.18
|
Rev Est: $185.0M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$14.33
DETAILS
HIGH:
$14.50
LOW:
$14.00
MEDIAN:
$14.50
CONSENSUS:
$14.33
DOWNSIDE:
0.21%
Market Cap:
4.50B
Volume:
2,352,004
Avg Volume:
11,208,961
52 Week Range:
5.51-14.38
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.43
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
499
IPO Date:
2007-05-31
EPS (TTM):
-0.09
P/E Ratio:
-161.97
Revenue (TTM):
634.21M
Total Assets:
949.87M
Total Debt:
442.36M
Cash & Equiv:
214.01M
Rev Growth (5Y):
19.4%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
4.8%
Debt/Equity:
1.61
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-04 | $0.17 | $0.12 | +41.7% | $169.1M | $185.0M | -8.6% |
| 2025-07-31 | $0.01 | $0.02 | -50.0% | $154.7M | $165.3M | -6.4% |
| 2025-05-01 | $0.03 | $0.08 | -62.5% | $125.2M | $147.5M | -15.1% |
| 2025-02-19 | $0.09 | $0.02 | +350.0% | $149.7M | $147.9M | +1.2% |
| 2024-11-06 | $0.10 | $0.08 | +25.0% | $141.5M | $147.4M | -4.0% |
| 2024-08-08 | $0.06 | $0.05 | +9.8% | $126.7M | $121.2M | +4.5% |
| 2024-05-09 | $-0.02 | $-0.06 | +66.7% | $110.4M | $111.2M | -0.7% |
| 2024-02-28 | $-0.11 | $-0.06 | -83.3% | $115.1M | $114.3M | +0.7% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 634.21M | 528.29M | 399.36M | 329.23M | 305.51M | 260.89M | 182.24M | 91.25M | 36.93M | 4.96M | 0 | 1.22M |
| Net Income | (27.11M) | (56.11M) | (151.58M) | (236.57M) | (250.46M) | (276.85M) | (356.39M) | (349.00M) | (284.00M) | (200.04M) | (132.12M) | (68.93M) |
| EPS | -0.09 | -0.18 | -0.51 | -0.82 | -0.92 | -1.07 | -1.48 | -1.88 | -1.85 | -1.49 | -1.20 | -0.93 |
| Total Assets | 949.87M | 785.03M | 777.88M | 724.17M | 905.14M | 886.52M | 850.21M | 789.95M | 627.02M | 1.04B | 908.38M | 209.97M |
| Total Debt | 442.36M | 443.64M | 445.06M | 452.12M | 440.13M | 441.73M | 210.22M | 321.74M | 164.47M | 154.46M | 41.60M | 14.35M |
| Cash & Equivalents | 214.01M | 213.75M | 246.99M | 148.81M | 245.20M | 163.24M | 142.84M | 79.75M | 49.06M | 187.03M | 69.48M | 24.07M |
| Operating Cash Flow | 33.15M | (33.89M) | (69.09M) | (166.57M) | (202.49M) | (233.29M) | (250.42M) | (299.95M) | (215.49M) | (150.53M) | (100.14M) | (51.67M) |
| Free Cash Flow | 29.85M | (37.44M) | (76.53M) | (170.34M) | (206.38M) | (236.52M) | (270.43M) | (306.26M) | (220.01M) | (156.49M) | (104.96M) | (51.91M) |
| FCF per Share | 0.10 | -0.12 | -0.26 | -0.59 | -0.76 | -0.91 | -1.12 | -1.65 | -1.43 | -1.16 | -0.95 | -0.70 |
| Book Value | 274.24M | 194.04M | 160.17M | 123.05M | 307.37M | 286.38M | 476.43M | 342.91M | 352.85M | 360.15M | 347.83M | 122.18M |
| Cash & ST Investments | 293.54M | 249.95M | 286.20M | 293.60M | 482.50M | 483.27M | 452.74M | 504.15M | 358.56M | 330.35M | 214.03M | 151.68M |
| ROC Equity | -0.10 | -0.29 | -0.95 | -1.92 | -0.81 | -0.97 | -0.75 | -1.02 | -0.80 | -0.56 | -0.38 | -0.56 |